226 related articles for article (PubMed ID: 36923309)
1. Repurposing Azacitidine and Carboplatin to Prime Immune Checkpoint Blockade-resistant Melanoma for Anti-PD-L1 Rechallenge.
van der Westhuizen A; Lyle M; Graves MC; Zhu X; Wong JWH; Cornall K; Ren S; Pugliese L; Levy R; Majid A; Vilain RE; Bowden NA
Cancer Res Commun; 2022 Aug; 2(8):814-826. PubMed ID: 36923309
[TBL] [Abstract][Full Text] [Related]
2. Pembrolizumab plus azacitidine in patients with chemotherapy refractory metastatic colorectal cancer: a single-arm phase 2 trial and correlative biomarker analysis.
Kuang C; Park Y; Augustin RC; Lin Y; Hartman DJ; Seigh L; Pai RK; Sun W; Bahary N; Ohr J; Rhee JC; Marks SM; Beasley HS; Shuai Y; Herman JG; Zarour HM; Chu E; Lee JJ; Krishnamurthy A
Clin Epigenetics; 2022 Jan; 14(1):3. PubMed ID: 34991708
[TBL] [Abstract][Full Text] [Related]
3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
4. Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer.
Fu S; Hu W; Iyer R; Kavanagh JJ; Coleman RL; Levenback CF; Sood AK; Wolf JK; Gershenson DM; Markman M; Hennessy BT; Kurzrock R; Bast RC
Cancer; 2011 Apr; 117(8):1661-9. PubMed ID: 21472713
[TBL] [Abstract][Full Text] [Related]
5. A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemia.
Saxena K; Herbrich SM; Pemmaraju N; Kadia TM; DiNardo CD; Borthakur G; Pierce SA; Jabbour E; Wang SA; Bueso-Ramos C; Loghavi S; Tang G; Cheung CM; Alexander L; Kornblau S; Andreeff M; Garcia-Manero G; Ravandi F; Konopleva MY; Daver N
Cancer; 2021 Oct; 127(20):3761-3771. PubMed ID: 34171128
[TBL] [Abstract][Full Text] [Related]
6. Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial.
D'Angelo SP; Bhatia S; Brohl AS; Hamid O; Mehnert JM; Terheyden P; Shih KC; Brownell I; Lebbé C; Lewis KD; Linette GP; Milella M; Georges S; Shah P; Ellers-Lenz B; Bajars M; Güzel G; Nghiem PT
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32414862
[TBL] [Abstract][Full Text] [Related]
7. Sequential azacitidine and carboplatin induces immune activation in platinum-resistant high-grade serous ovarian cancer cell lines and primes for checkpoint inhibitor immunotherapy.
Wong-Brown MW; van der Westhuizen A; Bowden NA
BMC Cancer; 2022 Jan; 22(1):100. PubMed ID: 35073851
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma.
Kreft S; Gesierich A; Eigentler T; Franklin C; Valpione S; Ugurel S; Utikal J; Haferkamp S; Blank C; Larkin J; Garbe C; Schadendorf D; Lorigan P; Schilling B
Eur J Cancer; 2019 Jul; 116():207-215. PubMed ID: 31212163
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis.
Goldinger SM; Buder-Bakhaya K; Lo SN; Forschner A; McKean M; Zimmer L; Khoo C; Dummer R; Eroglu Z; Buchbinder EI; Ascierto PA; Gutzmer R; Rozeman EA; Hoeller C; Johnson DB; Gesierich A; Kölblinger P; Bennannoune N; Cohen JV; Kähler KC; Wilson MA; Cebon J; Atkinson V; Smith JL; Michielin O; Long GV; Hassel JC; Weide B; Haydu LE; Schadendorf D; McArthur G; Ott PA; Blank C; Robert C; Sullivan R; Hauschild A; Carlino MS; Garbe C; Davies MA; Menzies AM
Eur J Cancer; 2022 Feb; 162():22-33. PubMed ID: 34952480
[TBL] [Abstract][Full Text] [Related]
10. Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma.
McGregor BA; Lalani AA; Xie W; Steinharter JA; E Bakouny Z; Martini DJ; Fleischer JH; Abou-Alaiwi S; Nassar A; Nuzzo PV; Kaymakcalan MD; Braun DA; Wei XX; Harshman LC; Bilen MA; Choueiri TK
Eur J Cancer; 2020 Aug; 135():203-210. PubMed ID: 32599410
[TBL] [Abstract][Full Text] [Related]
11. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.
Pires da Silva I; Ahmed T; Reijers ILM; Weppler AM; Betof Warner A; Patrinely JR; Serra-Bellver P; Allayous C; Mangana J; Nguyen K; Zimmer L; Trojaniello C; Stout D; Lyle M; Klein O; Gerard CL; Michielin O; Haydon A; Ascierto PA; Carlino MS; Lebbe C; Lorigan P; Johnson DB; Sandhu S; Lo SN; Blank CU; Menzies AM; Long GV
Lancet Oncol; 2021 Jun; 22(6):836-847. PubMed ID: 33989557
[TBL] [Abstract][Full Text] [Related]
12. Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy.
Bochem J; Zelba H; Spreuer J; Amaral T; Wagner NB; Gaissler A; Pop OT; Thiel K; Yurttas C; Soffel D; Forchhammer S; Sinnberg T; Niessner H; Meier F; Terheyden P; Königsrainer A; Garbe C; Flatz L; Pawelec G; Eigentler TK; Löffler MW; Weide B; Wistuba-Hamprecht K
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34933966
[TBL] [Abstract][Full Text] [Related]
13. Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.
Vilain RE; Menzies AM; Wilmott JS; Kakavand H; Madore J; Guminski A; Liniker E; Kong BY; Cooper AJ; Howle JR; Saw RPM; Jakrot V; Lo S; Thompson JF; Carlino MS; Kefford RF; Long GV; Scolyer RA
Clin Cancer Res; 2017 Sep; 23(17):5024-5033. PubMed ID: 28512174
[No Abstract] [Full Text] [Related]
14. Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade.
Gomez-Roca C; Cassier P; Zamarin D; Machiels JP; Perez Gracia JL; Stephen Hodi F; Taus A; Martinez Garcia M; Boni V; Eder JP; Hafez N; Sullivan R; Mcdermott D; Champiat S; Aspeslagh S; Terret C; Jegg AM; Jacob W; Cannarile MA; Ries C; Korski K; Michielin F; Christen R; Babitzki G; Watson C; Meneses-Lorente G; Weisser M; Rüttinger D; Delord JP; Marabelle A
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35577503
[TBL] [Abstract][Full Text] [Related]
15. Outcomes after progression of disease with anti-PD-1/PD-L1 therapy for patients with advanced melanoma.
Patrinely JR; Baker LX; Davis EJ; Song H; Ye F; Johnson DB
Cancer; 2020 Aug; 126(15):3448-3455. PubMed ID: 32463489
[TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates.
Liao JB; Gwin WR; Urban RR; Hitchcock-Bernhardt KM; Coveler AL; Higgins DM; Childs JS; Shakalia HN; Swensen RE; Stanton SE; Tinker AV; Wahl TA; Ancheta RG; McGonigle KF; Dai JY; Disis ML; Goff BA
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34531249
[TBL] [Abstract][Full Text] [Related]
17. Association of antibiotic treatment with survival outcomes in treatment-naïve melanoma patients receiving immune checkpoint blockade.
Chorti E; Kowall B; Hassel JC; Schilling B; Sachse M; Gutzmer R; Loquai C; Kähler KC; Hüsing A; Gilde C; Thielmann CM; Zaremba-Montenari A; Placke JM; Gratsias E; Martaki A; Roesch A; Ugurel S; Schadendorf D; Livingstone E; Stang A; Zimmer L
Eur J Cancer; 2024 Mar; 200():113536. PubMed ID: 38306840
[TBL] [Abstract][Full Text] [Related]
18. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
19. A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer.
Oza AM; Matulonis UA; Alvarez Secord A; Nemunaitis J; Roman LD; Blagden SP; Banerjee S; McGuire WP; Ghamande S; Birrer MJ; Fleming GF; Markham MJ; Hirte HW; Provencher DM; Basu B; Kristeleit R; Armstrong DK; Schwartz B; Braly P; Hall GD; Nephew KP; Jueliger S; Oganesian A; Naim S; Hao Y; Keer H; Azab M; Matei D
Clin Cancer Res; 2020 Mar; 26(5):1009-1016. PubMed ID: 31831561
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive analysis of tumor necrosis factor receptor TNFRSF9 (4-1BB) DNA methylation with regard to molecular and clinicopathological features, immune infiltrates, and response prediction to immunotherapy in melanoma.
Fröhlich A; Loick S; Bawden EG; Fietz S; Dietrich J; Diekmann E; Saavedra G; Fröhlich H; Niebel D; Sirokay J; Zarbl R; Gielen GH; Kristiansen G; Bootz F; Landsberg J; Dietrich D
EBioMedicine; 2020 Feb; 52():102647. PubMed ID: 32028068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
